Received Jun 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Z002903 | — |
second dose of GADASIL 9 received was "insufficient" due to "a lot of leakage during vaccination".; second dose of GADASIL 9 received was "insufficient" due to "a lot of leakage during vaccination".; second dose of GADASIL 9 received was "insufficient" due to "a lot of leakage during vaccination".; This spontaneous report was received from a Nurse and refers to a patient of not reported age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 03-JUN-2025, the patient was vaccinated with second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Z002903, expiration date reported as 03-DEC-2026 but upon internal validation was stated as 15-DEC-2026) (strength, dose description, route of administration not reported) for prophylaxis. It was reported that during vaccination the patient dose received was "insufficient" due to "a lot of leakage during vaccination. Nurse stated that the second dose was administered by a separate HCP and it was not reported that any leakage occurred at the time of vaccination and was unable to confirm if leakage occurred or if patient received less than recommended dose (vaccine underdose, device leakage, poor quality device used).